Atlas Trials

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Clinical trial NCT03506373 · TERMINATED

Trial details

NCT number
NCT03506373
Sponsor
Mayo Clinic
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Waldenstrom MacroglobulinemiaRefractory Waldenstrom MacroglobulinemiaWaldenstrom Macroglobulinemia
Start date
2018-08-14
Primary completion
2023-02-06
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.